Waystar Holding Corp.
No enriched coverage for $WAY in the last 7 days.
No SEC Form 4 filings for $WAY in the last 30 days.
See all $WAY insider activity →Analysts reiterated Buy ratings on Harmonic (HLIT) with a $20 target, Waystar (WAY) with a $33 target, and Jack Henry (JKHY) with a $178 target. Consensus targets are $17.50, $33.38, and $189.54 respectively. Analysts' track records and sector focuses were noted.
Skyworks Solutions (SWKS) and Qorvo (QRVO) rose 10% and 7% respectively, recovering from prior sell-offs. Axon (AXON) fell 9% after a $1B convertible note sale. Revvity (RVTY) jumped 7% to a 52-week high, citing strong backlog. Dave & Buster's (PLAY) dropped 17% after missing Q2 revenue and EBITDA estimates. Enova (ENVA) tumbled 25% after withdrawing a regulatory application. Sysco (SYY) slid 3% on a 12.3M share offering. Alignment Healthcare (ALHC) fell 18% due to business headwinds. Waystar (W
Waystar (WAY) shares rose 8% after Reuters reported the company is exploring a sale, with RBC naming Oracle (ORCL) as a potential buyer. Waystar hired Evercore to explore options, though no deal is guaranteed. RBC maintains an 'Outperform' rating with a $44 target, citing strong private-market valuations. Evercore also sees a sale as plausible given WAY's 24% decline this year.
Recent WAY coverage spans mergers & acquisitions, market movers and technology.
New target implies upside from current levels.
M&A speculation lifts the stock despite prior decline.
The sale exploration could lead to a takeover premium or private buyout, driving short-term upside.
Potential sale could trigger a valuation premium and M&A activity.
Exploratory sale process may attract acquisition interest.
AlphAI scores every news story that mentions WAY with an AI model for sentiment and relevance, and aggregates insider trades from Waystar Holding Corp.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Analysts reiterated Buy ratings on Harmonic (HLIT) with a $20 target, Waystar (WAY) with a $33 target, and Jack Henry (JKHY) with a $178 target. Consensus targets are $17.50, $33.38, and $189.54 respectively. Analysts' track records and sector focuses were noted.
2 min readSkyworks Solutions (SWKS) and Qorvo (QRVO) rose 10% and 7% respectively, recovering from prior sell-offs. Axon (AXON) fell 9% after a $1B convertible note sale. Revvity (RVTY) jumped 7% to a 52-week high, citing strong backlog. Dave & Buster's (PLAY) dropped 17% after missing Q2 revenue and EBITDA estimates. Enova (ENVA) tumbled 25% after withdrawing a regulatory application. Sysco (SYY) slid 3% on a 12.3M share offering. Alignment Healthcare (ALHC) fell 18% due to business headwinds. Waystar (W
2 min readWaystar (WAY) shares rose 8% after Reuters reported the company is exploring a sale, with RBC naming Oracle (ORCL) as a potential buyer. Waystar hired Evercore to explore options, though no deal is guaranteed. RBC maintains an 'Outperform' rating with a $44 target, citing strong private-market valuations. Evercore also sees a sale as plausible given WAY's 24% decline this year.
2 min readWaystar Holdings (WAY) shares rose Tuesday, crossing its 200-day average, on reports the medical software company is considering strategic options, including a potential sale. This follows the company's recent Investor Day event, which outlined growth plans.
2 min readU.S. stock futures fell on Tuesday due to higher Treasury yields, oil prices, and AI concerns. Sysco dropped 1.3% after a $1B stock offering for its Jetro acquisition. Waystar rose 3.3% on potential sale reports. Bitcoin fell 2.9%, affecting crypto-related stocks. Dave & Buster’s fell 11.2% after missing Q2 earnings estimates.
3 min readWaystar, a healthcare software firm, is exploring strategic options, including a potential sale, according to seven sources. The company, which went public in 2024, has hired Evercore as an advisor. Waystar's market value has dropped to $4.8 billion after a 24% decline in its share price this year. The company's strategy aims to leverage higher tech valuations, but investor concerns about AI disruption have pressured its stock.
2 min readWaystar (WAY) shares rose 3.3% premarket to $25.73 on reports it is exploring strategic options, including a potential sale. EQT (EQTAB) holds 13% of shares, with Canada Pension Plan and BlackRock (BLK) also as major stakeholders. The company went public in 2024.
1 min readHawkins Matthew J. (Chief Executive Officer) sold 82,500 shares of Waystar Holding Corp. (WAY) at $25.97 ($2.14M total) on 2026-09-02 under a Rule 10b5-1 trading plan.
2 min readWaystar (Nasdaq: WAY) launched new AI-driven agentic capabilities to autonomously execute revenue cycle workflows. Features include autonomous claim resolution, conversational analytics, and patient financial engagement. The company aims to reduce administrative work and improve financial outcomes for healthcare providers.
3 min readWaystar (NASDAQ:WAY) outlined its AI and automation strategy at its Investor Day, highlighting plans for new products and monetization paths. The company aims for low-double-digit revenue growth and adjusted EBITDA margins above 40%. Waystar also announced new executive hires and reported net leverage of 2.5 times, with plans to reduce debt.
3 min read
